Hansa Biopharma AB
https://hansabiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hansa Biopharma AB
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
2020 Sees Sharp Rise In EU New Drug Approvals
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
Hansa Biopharma To Be Transformed By Idefirix Approval In EU
With the first approval in the bag for its lead product, Idefirix, from the European Commission, Sweden’s Hansa Biopharma is planning to launch the product in Europe using its own medical and commercial organization in core markets.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Hansa Medical AB